Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma—correlation between radiation dose and radiation injury and clinical outcome

2006 ◽  
Vol 65 (5) ◽  
pp. 1446-1455 ◽  
Author(s):  
Teruyoshi Kageji ◽  
Shinji Nagahiro ◽  
Kazuhito Matsuzaki ◽  
Yoshifumi Mizobuchi ◽  
Hiroyuki Toi ◽  
...  
Keyword(s):  
Radiation Dose ◽  
Clinical Outcome ◽  
Malignant Glioma ◽  
Thermal Neutron ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Radiation Injury ◽  
Neutron Capture Therapy ◽  
Neutron Beams ◽  
Boron Neutron Capture

scholarly journals Thermal neutron Relative Biological Effectiveness factors for Boron Neutron Capture Therapy from In Vitro Irradiations

2020 ◽  
Author(s):  
María Pedrosa-Rivera ◽  
Javier Praena ◽  
Ignacio Porras ◽  
Manuel Pedro Sabariego ◽  
Ulli Köster ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Thermal Neutron ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Relative Biological Effectiveness ◽  
Neutron Capture Therapy ◽  
Tumor Cell Lines ◽  
Boron Neutron Capture ◽  
Effectiveness Factors ◽  
Biological Effectiveness

The experimental determination of the relative biological effectiveness of thermal neutron factors is fundamental in Boron Neutron Capture Therapy. Present values have been obtained using mixed beams consisting of both neutrons and photons of various energies. A common weighting factor has been used for both thermal and fast neutron doses, although such an approach has been questioned. At the nuclear reactor of the Institut Laue-Langevin a pure low-energy neutron beam has been used to determine thermal neutron relative biological effectiveness factors. Different tumor cell lines, corresponding to glioblastoma, melanoma, and head and neck squamous cell carcinoma, and non-tumor cell lines (lung fibroblast and embryonic kidney) have been irradiated using an experimental arrangement designed to minimise neutron-induced secondary gamma radiation. Additionally, the cells were irradiated with photons at a medical linear accelerator, providing reference data for comparison with that from neutron irradiation. Survival and proliferation were studied after irradiation, yielding the Relative Biological Effectiveness corresponding to the damage of thermal neutrons for the different tissue types.

scholarly journals Boron Neutron Capture Therapy and Add-on Bevacizumab in Patients with Recurrent Malignant Glioma

2021 ◽  
Author(s):  
Motomasa Furuse ◽  
Shinji Kawabata ◽  
Masahiko Wanibuchi ◽  
Hiroyuki Shiba ◽  
Koji Takeuchi ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Boron Neutron Capture Therapy ◽  
Survival Data ◽  
Neutron Capture ◽  
Radiation Necrosis ◽  
Neutron Capture Therapy ◽  
Recurrent Malignant Glioma ◽  
Primary Glioblastoma ◽  
Boron Neutron Capture ◽  
Grade 3

Abstract Introduction: Boron neutron capture therapy (BNCT) has shown excellent survival data but increases in radiation necrosis against recurrent malignant glioma (MG) in previous studies. We proposed that bevacizumab may reduce radiation injury from BNCT by re-irradiation. We evaluated the efficacy and safety of a combination therapy of BNCT and add-on bevacizumab in patients with recurrent MG.Methods: Patients with recurrent MG were treated with reactor-based BNCT. Treatment with bevacizumab (10 mg/kg) was initiated 1–4 weeks after BNCT irradiation and was re-administered every 2–3 weeks until disease progression. Initially diagnosed glioblastomas were categorized as primary glioblastoma (pGBM) and other forms of MG were categorized as non-pGBM. Results: Twenty-five patients (14 with pGBM and 11 with non-pGBM) were treated with BNCT and add-on bevacizumab. The 1-year survival rate for pGBM and non-pGBM was 63.5% (95% CI, 33.1–83.0) and 81.8% (95%CI, 44.7–95.1), respectively. The median OS was 21.4 months (95% CI, 7.0–36.7) and 73.6 months (95% CI, 11.4–77.2) for pGBM and non-pGBM, respectively (p = 0.0428). The median PFS was 8.3 months (95%CI, 4.2–12.1) and 15.6 months (95% CI, 3.1–29.8) for pGBM and non-pGBM, respectively (p = 0.0207). Alopecia occurred in all patients. Six patients experienced adverse events ≥ grade 3.Conclusions: BNCT and add-on bevacizumab were found to provide both a long OS and a long PFS, compared to the previous studies of BNCT alone for recurrent MG. The add-on bevacizumab may reduce the detrimental effects of BNCT radiation, including pseudoprogression and radiation necrosis.

Sign in / Sign up

Export Citation Format

Share Document